Showing results (1-10 of 178) with videos related to
Sort By:
Pageof 18
Pharmacology, Biochemistry, and Behavior|August 23, 2024
ANXIOLYTICS: Origins, drug discovery, and mechanismsJeffrey M Witkin, James E BarrettCurrent Protocols in Neuroscience|October 31, 2008
Animal models of obsessive-compulsive disorderJeffrey M WitkinPharmacology, Biochemistry, and Behavior|January 20, 2020
mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effectsJeffrey M WitkinPsychopharmacology|October 10, 2002
Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of ratsJeffrey M WitkinAdvances in Pharmacology (San Diego, Calif.)|March 17, 2010
New approaches to the pharmacological management of major depressive disorderJeffrey M Witkin, Xia LiCNS & Neurological Disorders Drug Targets|April 12, 2013
Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacyJeffrey M Witkin, Xia LiBiochemical Pharmacology|January 14, 2018
Protein complexes as psychiatric and neurological drug targetsAkihiko S Kato, Jeffrey M WitkinBiochemical Pharmacology|October 9, 2017
Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481/CERC-611Akihiko S Kato, Jeffrey M WitkinCurrent Drug Targets|May 17, 2007
AMPA receptor potentiators: application for depression and Parkinson's diseaseMichael J O'Neill, Jeffrey M WitkinPsychopharmacology|April 1, 2006
Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidineScott D Gleason, Jeffrey M WitkinPageof 18